| 000 | 01850 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250516224112.0 | ||
| 264 | 0 | _c20150611 | |
| 008 | 201506s 0 0 eng d | ||
| 022 | _a1569-8041 | ||
| 024 | 7 |
_a10.1093/annonc/mdu273 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aInwards, D J | |
| 245 | 0 | 0 |
_aPhase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphoma. _h[electronic resource] |
| 260 |
_bAnnals of oncology : official journal of the European Society for Medical Oncology _cOct 2014 |
||
| 300 |
_a2020-2024 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Murine-Derived _xadministration & dosage |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xadministration & dosage |
| 650 | 0 | 4 |
_aCladribine _xadministration & dosage |
| 650 | 0 | 4 | _aDisease-Free Survival |
| 650 | 0 | 4 |
_aDrug-Related Side Effects and Adverse Reactions _xpathology |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLymphoma, Mantle-Cell _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNeoplasm Recurrence, Local _xdrug therapy |
| 650 | 0 | 4 | _aRemission Induction |
| 650 | 0 | 4 | _aRituximab |
| 650 | 0 | 4 |
_aSirolimus _xadministration & dosage |
| 700 | 1 | _aFishkin, P A | |
| 700 | 1 | _aLaPlant, B R | |
| 700 | 1 | _aDrake, M T | |
| 700 | 1 | _aKurtin, P J | |
| 700 | 1 | _aNikcevich, D A | |
| 700 | 1 | _aWender, D B | |
| 700 | 1 | _aLair, B S | |
| 700 | 1 | _aWitzig, T E | |
| 773 | 0 |
_tAnnals of oncology : official journal of the European Society for Medical Oncology _gvol. 25 _gno. 10 _gp. 2020-2024 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1093/annonc/mdu273 _zAvailable from publisher's website |
| 999 |
_c24038141 _d24038141 |
||